Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ARQ 736 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| ARQ 736 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| ARQ 736 | DRUG | Subjects in this study will receive ARQ 736 orally at dose levels specified for their respective dose cohorts. Dosing will begin at 900 mg/day (first cohort) and escalate until the recommended Phase 2 dose or maximum tolerated dose is determined. Cycles will be repeated in four-week (28-day) intervals until progression of disease, unacceptable toxicity, or another discontinuation criterion is met. In the case of toxicity, dose adjustment will be permitted. |
Inclusion Criteria: * Signed written informed consent granted prior to initiation of any study-specific procedures * Male or female subjects of ≥ 18 years of age * All subjects must be positive for a BRAF and/or NRAS mutation * Histologically or cytologically confirmed locally advanced, inoperable ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
ARQ 736 is an investigational small molecule being studied for the treatment of solid tumors. It is in Phase 1 clinical development for advanced solid tumors that harbor BRAF and/or NRAS mutations. The drug is being developed by Merck & Company, Inc. (MRK).
ARQ 736 is being studied in solid tumors that harbor BRAF and/or NRAS mutations. The clinical trial for ARQ 736 specifically enrolls adult subjects with advanced solid tumors harboring these mutations, indicating that the drug is being evaluated in a mutation-selected patient population.
ARQ 736 is being developed by Merck & Company, Inc., which trades under the ticker symbol MRK. The drug is currently in Phase 1 clinical development for the treatment of solid tumors.
ARQ 736 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. A Phase 1 dose escalation study of ARQ 736 in adult subjects with advanced solid tumors has been completed.
ARQ 736 has one completed clinical trial, NCT01225536, titled "Dose Escalation Study of ARQ 736 in Adult Subjects With Advanced Solid Tumors Harboring BRAF and/or NRAS Mutations." This Phase 1 study enrolled 24 participants and was conducted in the United States and Italy.
ARQ 736 is the drug name used in clinical development. No alternative names for ARQ 736 have been disclosed in the available clinical trial information.